Latest Schedule 13G passive stakes

TCG Crossover entities and Chen Yu have amended their Schedule 13G filing to reflect updated beneficial ownership of ALX Oncology Holdings Inc. common stock.

Jeffrey L. Gendell, through affiliated entities, has reported beneficial ownership of 614,230 shares, representing 4.4% of Nine Energy Service, Inc.'s common stock.

Pentwater Capital Management LP and Matthew Halbower have jointly reported beneficial ownership of 5.9% of TXNM Energy, Inc. common stock.

TCG Crossover entities have filed an amendment to their Schedule 13G, reporting a combined beneficial ownership of 7.0% in Abivax SA ordinary shares following a recent offering.

Pentwater Capital Management LP and Matthew Halbower have reported a change in their beneficial ownership of AMC Entertainment Holdings, Inc. Class A Common Stock.

Paradigm BioCapital Advisors LP and its affiliates have reported beneficial ownership of 5.3% of Lexeo Therapeutics, Inc. common stock as of June 30, 2026.

Montanova Capital, Averill Master Fund, and Aaron Cowen have collectively increased their beneficial ownership in Fulcrum Therapeutics to 5.5% and 3.8% respectively, as of June 30, 2026.

Biotechnology Value Fund and associated entities have disclosed a significant beneficial ownership stake of 9.99% in Tenax Therapeutics, Inc., primarily through pre-funded warrants and warrants.

Paradigm BioCapital Advisors LP and its affiliates have reported beneficial ownership of 9.5% of Edgewise Therapeutics, Inc. common stock as of June 30, 2026.

Alyeska Investment Group, L.P. and related entities have reported beneficial ownership of 7.01% of Bleichroeder Acquisition Corp. II's Class A ordinary shares.

Pentwater Capital Management LP and Matthew Halbower have filed a Schedule 13G, reporting beneficial ownership of 0.4% of Core Scientific, Inc. common stock.

Battery Ventures entities have updated their beneficial ownership filings for Braze, Inc., reporting changes in their holdings as of June 30, 2026.

Paradigm BioCapital entities and Senai Asefaw have filed an amendment to their Schedule 13G, reporting no change in beneficial ownership of Maze Therapeutics common stock as of June 30, 2026.

Alyeska Investment Group, L.P., along with affiliated entities, has reported beneficial ownership of 4.73% of SunPower Inc.'s common stock as of June 30, 2026.

Pentwater Capital Management LP and Matthew Halbower have reported zero beneficial ownership of Centessa Pharmaceuticals plc's ordinary shares, signaling a complete divestment.

AWM Investment Company, Inc. has filed a Schedule 13G, disclosing a 1.1% beneficial ownership of AEHR Test Systems' common stock as of June 30, 2026.

TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC, along with Chen Yu, have filed an amendment to their Schedule 13G for Fulcrum Therapeutics, Inc., reporting no change in beneficial ownership.

OceanLink Partners Fund, LP has disclosed beneficial ownership of 4.72% of Atour Lifestyle Holdings Ltd's Class A ordinary shares, represented by American Depositary Shares.

Pentwater Capital Management LP and Matthew Halbower have jointly filed a Schedule 13G, reporting beneficial ownership of 11,465,000 shares, or 5.6%, of Caesars Entertainment, Inc. common stock.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amendment to its Schedule 13G, reporting beneficial ownership of 539,892 shares of BNB PLUS CORP. common stock, representing 7.0% of the class.

Several Biotechnology Value Funds and associated entities have updated their beneficial ownership filings for TScan Therapeutics, Inc., reporting their holdings as of June 30, 2026.

Alyeska Investment Group, L.P., along with its affiliates, has reported beneficial ownership of 4.86% of Abundia Global Impact Group, Inc.'s common stock as of June 30, 2026.

D. E. Shaw & Co., L.P., D. E. Shaw & Co., L.L.C., and David E. Shaw have filed an amendment to their Schedule 13G, updating their beneficial ownership information for Cable One, Inc.

Alyeska Investment Group, L.P., along with affiliated entities, has reported a beneficial ownership stake of 4.61% in USA Rare Earth, Inc., as of June 30, 2026.

HighSage Ventures LLC and Jennifer Stier have jointly filed a Schedule 13G, reporting a combined beneficial ownership of approximately 6.9% to 7% of Angi Inc.'s Class A Common Stock as of June 30, 2026.

Redmile Group, LLC, Jeremy C. Green, and RedCo II Offshore SPV LLC have updated their beneficial ownership filings for Nurix Therapeutics, Inc., collectively holding 8.1% and 3.5% of the common stock.

Encompass Capital Advisors LLC, Todd J. Kantor, and Encompass Capital Partners LLC have filed an amended Schedule 13G, reporting zero beneficial ownership of Rice Acquisition Corp's Class A common stock.

Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have jointly filed a Schedule 13G, reporting beneficial ownership of 1.16% of Voyager Technologies, Inc.'s Class A Common Stock as of June 30, 2026.

J. Goldman & Co LP, along with affiliated entities, has reported beneficial ownership of 1,696,549 shares, representing 5.57% of Destiny Tech100 Inc.'s common stock.

TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu have jointly reported beneficial ownership of 500,000 Class A Ordinary Shares, representing 6.4% of the outstanding shares in Research Alliance Corporation III.